Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Prior treatment

• Prior intra-articular injection to the target joint of steroids, hyaluronate or other drugs within 3 months prior to treatment.
• Any significant injury to the target joint within the 6 months prior to treatment, or any surgery to the target joint within the 12 months prior to treatment.
• Concomitant rheumatic, inflammatory or autoimmune disease other than PsA.

Other illness

• Evidence of active local infection in the target joint.
• Any evidence of clinically significant active infection.
• Major medical condition as detailed in the protocol.

Other

• Findings of acute fractures, severe loss of bone density, chondrocalcinosis and/or severe bone or joint deformity in the target joint.
• Other limb pain of unknown etiology.

• Diagnosed with PsA.
• Stage 1 patients:
  • At least one joint resistant to standard PsA treatments and on a stable dose of approved PsA treatment for at least 3 months prior to treatment.
• Stage 2 patients:
  • At least one symptomatic joint following attempt of intra-articular injection of corticosteroids, with insufficient response.
• Acceptable blood tests- Complete Blood Count (CBC), electrolytes, adequate renal function, adequate liver function.